IFNA1 and myeloid sarcoma: The aim of this study was to explore the COI progression in MS among newly diagnosed people with MS (PwMS) in Sweden, in relation to the first DMT received (interferons (IFN) vs glatiramer acetate (GA) vs natalizumab (NAT)), adjusting for disability progression over time.